[A20-63] Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2020
Project no.:
A20-63
Commission:
Commission awarded on 24.07.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
| Children from 3 years to < 12 years of age with chronic hepatitis C |
Result of dossier assessment:
| Genotype 1 and 4: hint of non-quantifiable added benefit; genotype 3, 5 and 6: added benefit not proven |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-41 | Ledipasvir/sofosbuvir (hepatitis C) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-44 | Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |